Just a little reading on the side has me looking at another biotech which has a MC about twice ours. These guys are just about to start in 2H2019 a phase 2 for an issue called critical limb ischemia. Now we are going to be announcing our phase 2 acne results in a few months time and from where I sit, the market potential of our product seems much much higher. Let alone phase 2 atopic dermatitis. Let alone the incoming news on psoriasis efficacy. We know phase 1b is about safety too. There is no issue with us. It is hard to believe that we are the same price as in June 2018. Frustrating, definately. But if you were to sell now then you may have rocks in your head.
-
- There are more pages in this discussion • 1,144 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $588.2M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.0¢ | 30.0¢ | $2.131M | 7.020M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 504695 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 38124 | 3 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| BOT (ASX) Chart |